JPRN-UMIN000031337招募中未知
Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia - Sucroferric oxyhydroxide against hyperphosphatemia
Dialysis Center, JA Toride Medical Center0 个研究点目标入组 20 人开始时间: 2018年2月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients with risk od aspiration
研究者
相似试验
已完成
不适用
Study of the efficacy of sucroferric oxyhydroxide (chewable tablet) on the control of CKD-MBD and improvement of renal anemia in hemodialysis patients with hyperphosphatemia.Hyperphosphatemia in chronic kidney disease patients on hemodialysisJPRN-UMIN000023657Kawashima Hospital, Social Medical Corporation Kawashima Hospital Group50
已完成
不适用
Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patientsChronic kidney diseaseJPRN-UMIN000032867Department of Nephrology, hypertension and Endocrinology, Nihon University School of Medicine60
已完成
1 期
The Effect of the Antioxidant (GliSODin) on Unexplained FatigueFatigueMetabolic and Endocrine - Other metabolic disordersACTRN12607000420448Applied Science & Nutrition40
已完成
不适用
The effects of oral administration of bulleyaconitine A in postherpetic neuralgiaISRCTN16975505Xinhua Hospital affiliated with Shanghai Jiaotong University School of Medicine120
尚未招募
1 期
Safety of Orally Administered Neutral pH Super Oxidation Electrolyzed SolutioHealthyHealthy VolunteersRPCEC00000427Esteripharma Laboratory30